气体分析呼吸
呼出气冷凝液
肺癌
生物标志物
医学
呼气
癌症
肺
内科学
肿瘤科
病理
放射科
生物
生物化学
解剖
哮喘
作者
Yijing Long,Chunyan Wang,Tianzhi Wang,Wenwen Li,Wei Dai,Shao-Hua Xie,Yonghui Tian,Mingxin Liu,Yifeng Liu,Xiaoqin Peng,Yuanling Liu,Yinchenxi Zhang,Ruxin Wang,Qiang Li,Yixiang Duan
出处
期刊:Journal of Breath Research
[IOP Publishing]
日期:2020-08-12
卷期号:15 (1): 016017-016017
被引量:23
标识
DOI:10.1088/1752-7163/abaecb
摘要
Abstract Exhaled breath analysis has emerged as a promising non-invasive method for diagnosing lung cancer (LC), whereas reliable biomarkers are lacking. Herein, a standardized and systematic study was presented for LC diagnosis, classification and metabolism exploration. To improve the reliability of biomarkers, a validation group was included, and quality control for breath sampling and analysis, comprehensive pollutants analysis, and strict biomarker screening were performed. The performance of exhaled breath biomarkers was shown to be excellent in diagnosing LC even in early stages (stage I and II) with surpassing 0.930 area under the receiver operating characteristic (ROC) curve (AUC), 90% of sensitivity and 88% of specificity both in the discovery and validation analyses. Meanwhile, in these two groups, diagnosing subtypes of LC attained AUCs over 0.930 and reached 1.00 in the two subtypes of adenocarcinomas. It is demonstrated that the metabolism changes in LC are possibly related to lipid oxidation, gut microbial, cytochrome P450 and glutathione S-transferase, and glutathione pathways change in LC progression. Overall, the reliable biomarkers contribute to the clinical application of breath analysis in screening LC patients as well as those in early stages.
科研通智能强力驱动
Strongly Powered by AbleSci AI